<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008055</url>
  </required_header>
  <id_info>
    <org_study_id>D361FC00001</org_study_id>
    <secondary_id>2021-000870-27</secondary_id>
    <nct_id>NCT05008055</nct_id>
  </id_info>
  <brief_title>Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
  <acronym>CAPITAL</acronym>
  <official_title>A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multicenter Phase II study of capivasertib administered orally&#xD;
      in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol follows a modular design. The study will investigate the safety and&#xD;
      efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL),&#xD;
      Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 13, 2021</start_date>
  <completion_date type="Anticipated">April 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with objective response</measure>
    <time_frame>Until progression of disease [PD] (Assessed Up to 1.6 Years)</time_frame>
    <description>Estimation of effectiveness of the capivasertib by assessment of objective response rate (ORR). The ORR is defined as the proportion of participants achieving either complete response (CR) or partial response (PR) according to the Lugano 2014 Classification for NHL as assessed by blinded independent central review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Screening (days -28 to -1), Weeks 8, 16, 24, 36, 48, and 60 and thereafter every 24 weeks for FL/MZL and every 12 weeks for MCL, until PD (Assessed Up to 1.6 Years)</time_frame>
    <description>Estimation of effectiveness of the capivasertib by assessment of DoR. The DoR is defined as the time from the date of first documented response until date of documented progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Screening (days -28 to -1), Weeks 8, 16, 24, 36, 48, and 60 and thereafter every 24 weeks for FL/MZL and every 12 weeks for MCL, until PD (Assessed Up to 1.6 Years)</time_frame>
    <description>Estimation of effectiveness of the capivasertib by assessment of progression-free survival. Progression-free survival is defined as the time from the date of first dose until documented disease progression according to the Lugano 2014 classification for NHL as assessed by BICR, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Until Death due to any cause (Assessed Up to 1.6 Years)</time_frame>
    <description>Estimation of effectiveness of the capivasertib by assessment of OS. Overall survival is defined as time from the date of first dose until the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality of life as measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Cycle 1 (28-day treatment Cycle) Day 1 and every 4 weeks from Cycle 1 Day 1 for the first 24 weeks and then every 12 weeks thereafter until 12 weeks post progression</time_frame>
    <description>Assessment of patient-reported disease-related symptoms, functioning and health-related quality of life as measured by EORTC QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants reporting symptomatic adverse events (AEs) and overall side effect burden at each time point as measured by Patient Global Impression of Treatment Tolerability (PGI-TT)</measure>
    <time_frame>Cycle 1 (28-day treatment Cycle) Day 1, every week from Cycle 1 Day 1 for the first 4 weeks, every 4 weeks for the next 8 weeks, and every 12 weeks afterwards until EOT and Post treatment follow-up (Assessed Up to 1.6 Years)</time_frame>
    <description>Assessment of patient-reported symptomatic AEs as measured by PGI-TT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Cancer Institute patient-reported outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) symptoms</measure>
    <time_frame>Cycle 1 (28-day treatment Cycle) Day 1, every week from Cycle 1 Day 1 for the first 4 weeks, every 4 weeks for the next 8 weeks, and every 12 weeks afterwards until EOT and Post treatment follow-up (Assessed up to 1.6 Years)</time_frame>
    <description>Assessment of patient-reported symptomatic AEs/tolerability of capivasertib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent therapy or death (TFST)</measure>
    <time_frame>Until first subsequent anti-lymphoma therapy or Death due to any cause (Assessed Up to 1.6 Years )</time_frame>
    <description>Estimation of the effectiveness of capivasertib by TFST. The TFST is defined as time from date of first dose until the start date of first subsequent anti-lymphoma therapy after discontinuation of study treatment or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to objective response (TTR)</measure>
    <time_frame>From Cycle 1 (28-day treatment cycle) Day 1 until documented response (also until PD/Death for those who never respond) [Assessed Up to 1.6 Years]</time_frame>
    <description>Estimation of effectiveness of the capivasertib by assessment of TTR. The TTR is defined as as time from date of first dose until the date of first documented objective response per the Lugano 2014 Classification for NHL as assessed by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AEs and Serious adverse events</measure>
    <time_frame>Screening (Day -28 to -1) until Post-treatment follow-up (30 days after last dose) or long-term follow-up (Every 12 weeks) [Assessed up to 1.6 Years]</time_frame>
    <description>Assessment of safety and tolerability of the capivasertib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed lowest drug concentration reached before the next dose is administered (Ctrough) of capivasertib</measure>
    <time_frame>Pre-dose on Cycle 1 (28-day treatment Cycle) Day 1 and on Cycle 1 Day 8, Cycle 1 Day 15 and Cycle 1 Day 22</time_frame>
    <description>Determination of plasma concentration of capivasertib pre-dose (Ctrough).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of capivasertib post-dose</measure>
    <time_frame>Cycle 1 (28-day treatment Cycle) Day 1: 1 hour, 2 hour and 4 hour post-dose</time_frame>
    <description>Determination of plasma concentration of capivasertib post-dose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Relapsed or Refractory B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Capivasertib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capivasertib</intervention_name>
    <description>Capivasertib will be given twice a day, intermittently.</description>
    <arm_group_label>Capivasertib monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be ≥ 18 years of age, at the time of signing the informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Female participants must not be breast-feeding and must have a negative pregnancy test&#xD;
             prior to start of dosing&#xD;
&#xD;
        Module 1 specific inclusion criteria:&#xD;
&#xD;
        Additional Inclusion Criteria for Cohort 1A (R/R FL):&#xD;
&#xD;
          1. Histologically confirmed diagnosis of FL Grade 1, 2, or 3a as assessed by investigator&#xD;
             or local pathologist&#xD;
&#xD;
          2. Current need for systemic treatment based on the Investigator's opinion&#xD;
&#xD;
          3. Relapsed, progressed or refractory (defined as failure to achieve at least a partial&#xD;
             response [PR]) after at least 2 prior systemic lines of therapy (including&#xD;
             anti-CD20mAb and an alkylating agent)&#xD;
&#xD;
          4. Participants should have received up to a maximum of 5 lines of prior therapies.&#xD;
&#xD;
          5. Bi-dimensionally measurable disease on cross sectional imaging by computed tomography&#xD;
             (CT) or magnetic resonance imaging (MRI) with at least one nodal lesion &gt; 1.5 cm in&#xD;
             the long axis or at least one extranodal lesion &gt; 1 cm in long axis.&#xD;
&#xD;
        Additional Inclusion Criteria for Cohort 1B (R/R MZL):&#xD;
&#xD;
          1. Histologically confirmed MZL including splenic, nodal, and extranodal subtypes as&#xD;
             assessed by investigator or local pathologist&#xD;
&#xD;
          2. Current need for systemic treatment based on the Investigator's opinion&#xD;
&#xD;
          3. Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after&#xD;
             at least 2 prior systemic lines of therapy (including at least one anti-CD20mAb&#xD;
             directed regimen either as monotherapy or as chemoimmunotherapy; Helicobacter pylori&#xD;
             eradication and radiation therapy alone will not be considered a systemic treatment&#xD;
             regimen)&#xD;
&#xD;
          4. Participants should have received up to a maximum of 5 lines of prior therapies&#xD;
&#xD;
          5. Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at&#xD;
             least one nodal lesion &gt; 1.5 cm in the long axis or at least one extranodal lesion &gt; 1&#xD;
             cm in long axis&#xD;
&#xD;
        Additional Inclusion Criteria for Cohort 1C (R/R MCL):&#xD;
&#xD;
          1. Histologically confirmed MCL, with documentation of monoclonal B cells that have a&#xD;
             chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1, as assessed&#xD;
             by investigator or local pathologist&#xD;
&#xD;
          2. Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after&#xD;
             at least 2 prior systemic lines of therapy&#xD;
&#xD;
          3. Participants should have received up to a maximum of 4 lines of prior therapies&#xD;
&#xD;
             Prior regimens must have included:&#xD;
&#xD;
               -  BTK inhibitor and&#xD;
&#xD;
               -  Anti-CD20 monoclonal antibody therapy&#xD;
&#xD;
          4. Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at&#xD;
             least one nodal lesion &gt; 1.5 cm in the long axis or at least one extranodal lesion &gt; 1&#xD;
             cm in long axis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignancy (other than the disease under study), except for adequately treated&#xD;
             basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which&#xD;
             the participant has been disease free for ≥ 2 years&#xD;
&#xD;
          -  With the exception of alopecia, any unresolved non-haematological toxicities from&#xD;
             prior therapy ≥ Common Terminology Criteria for Adverse Events Grade 2 at the time of&#xD;
             starting study treatment&#xD;
&#xD;
          -  Known medically apparent central nervous system lymphoma or leptomeningeal disease&#xD;
&#xD;
          -  Inadequate bone marrow reserve or organ function as demonstrated by any of the&#xD;
             following laboratory values at screening:&#xD;
&#xD;
               1. Absolute neutrophil count &lt; 1.0 × 10^9/L; &lt; 0.75 × 10^9/L in participants with&#xD;
                  known bone marrow involvement of malignant disease&#xD;
&#xD;
               2. Platelets &lt; 75 × 10^9/L; &lt; 50 × 10^9/L in participants with known bone marrow&#xD;
                  involvement of malignant disease&#xD;
&#xD;
               3. Creatinine clearance &lt; 50 mL/min per the Cockcroft and Gault formula&#xD;
&#xD;
          -  Clinically significant abnormalities of glucose metabolism as participants with&#xD;
             diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment and&#xD;
             Glycosylated haemoglobin ≥ 8.0% (63.9 mmol/mol)&#xD;
&#xD;
          -  Prior treatment with any of the following:&#xD;
&#xD;
               1. Any investigational agents or study drugs from a previous clinical study within 5&#xD;
                  half lives or 2 weeks from the first dose of capivasertib in this study&#xD;
&#xD;
               2. Potent inhibitors or inducers of CYP3A4 and/or UGT2B7 within 2 weeks prior to the&#xD;
                  first dose of study treatment (3 weeks for St John's wort), or sensitive&#xD;
                  substrates of CYP3A4, CYP2C9 and/or CYP2D6 with a narrow therapeutic window&#xD;
                  within 1 week prior to the first dose of study treatment&#xD;
&#xD;
               3. Prior allogenic Haematopoietic stem cell transplant (HSCT) within 6 months from&#xD;
                  the first dose of capivasertib (patients &gt; 6 months after allogenic HSCT are&#xD;
                  eligible in the absence of active graft-versus-host disease and concomitant&#xD;
                  immune suppressive therapy). Prior cellular therapies (eg, Chimeric antigen&#xD;
                  receptor T therapy) and/or autologous HSCT within 3 months from the first dose of&#xD;
                  capivasertib&#xD;
&#xD;
               4. Receipt of live, attenuated vaccine within 28 days before the first dose of study&#xD;
                  treatment(s)&#xD;
&#xD;
               5. Participants who, due to other medical conditions /prior history /concomitant&#xD;
                  medications are, in the investigator's opinion, at a risk of a venous&#xD;
                  thromboembolism (VTE) and are not willing to accept the VTE prophylaxis, will be&#xD;
                  excluded. The initiation of an adequate VTE prophylaxis will be based on treating&#xD;
                  physician risk/benefit assessment and in agreement with the local management&#xD;
                  guidelines&#xD;
&#xD;
        Additional exclusion core criteria may apply, please refer to the protocol&#xD;
&#xD;
        Module 1 specific exclusion criteria:&#xD;
&#xD;
          1. Follicular lymphoma grade 3B&#xD;
&#xD;
          2. Known transformation to aggressive lymphoma, eg, large cell lymphoma&#xD;
&#xD;
          3. MCL participants with blastoid or pleiomorphic variant or documented tumour protein 53&#xD;
             mutation at study entry/most recent relapse&#xD;
&#xD;
          4. Participants who, in the Investigator's opinion, require immediate cytoreductive&#xD;
             therapy for disease control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>DK8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seo-Gu</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Marginal Zone Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Capivasertib monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at:&#xD;
https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patientlevel data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:&#xD;
https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

